PRL expression in the human uterus is up-regulated during the mid to late secretory phase of the menstrual cycle. This coincides with up-regulation of the expression of the PRL receptor, which is localized primarily to the endometrial glandular epithelial cells. Recent data have demonstrated activation of the Jak (Janus kinase)/Stat (signal transducer and activator of transcription) signaling pathway in the secretory endometrium after stimulation with exogenous PRL. However, the target genes for the action of PRL on the endometrial epithelial cells have not been elucidated. In this study we have investigated the pattern/site of expression of the transcription factor interferon regulatory factor-1 (IRF-1) as well as the effect of exogenous PRL on the transcription of IRF-1 in the human endometrium during the mid to late secretory phase of the menstrual cycle. Expression of the IRF-1 gene was confirmed by RNase protection assays using a 260-bp homologous [␣- T HE UTERUS is one of the first extrapituitary sites that has been described to synthesize and secrete the hormone PRL (1). In the nonpregnant uterus PRL synthesis is detected between the midsecretory phase and menses and coincides with the first histological signs of decidualization. If pregnancy occurs, the decidual cells differentiate, and decidual PRL synthesis increases after implantation, reaches a peak at 20 -25 weeks of pregnancy, and declines toward term (2, 3). PRL exerts its effect through interaction with single transmembrane-spanning receptors that belong to the superfamily of cytokine receptors (4 -6). In the nonpregnant endometrium, PRL receptor expression is detected and localized to the stromal and glandular compartments during the mid-late secretory phase of the menstrual cycle (7, 8) . If pregnancy ensues, PRL receptor expression is retained in the decidua and is further expressed in the chorionic cytotrophoblast, placental trophoblast, and amniotic epithelium (9). The precise role and mechanism of action of PRL in the nonpregnant and pregnant endometrium has not been clarified. The temporal pattern of expression of both PRL and its receptor in the human endometrium suggests a possible role for the hormone in menstrual function and/or the establishment and maintenance of pregnancy. A role for PRL in the regulation of menstruation is not properly established and is inferred from the observations that PRL concentrations in menstrual fluid on day 1 of menses are 5-fold higher than the median peripheral PRL concentrations (10) and that defective secretory endometrium produces less PRL than normal endometrium (11). On the other hand, a role for PRL in pregnancy is more widely accepted. This view is strongly supported by recent observations in mice after the knockout of the PRL receptor gene. Female mice with a homozygous null mutation of the PRL receptor are sterile, and their uteri are refractory to implantation (12).
P]UTP-labeled IRF-1 complementary ribonucleic acid (RNA) probe and 10 g total RNA extracted from human endometrium (n ϭ 5) collected between days 19 and 26 of the menstrual cycle. Northern and Western blot analyses were conducted on secretory phase human endometrium (n ϭ 3) using human [␣- 32 T HE UTERUS is one of the first extrapituitary sites that has been described to synthesize and secrete the hormone PRL (1) . In the nonpregnant uterus PRL synthesis is detected between the midsecretory phase and menses and coincides with the first histological signs of decidualization. If pregnancy occurs, the decidual cells differentiate, and decidual PRL synthesis increases after implantation, reaches a peak at 20 -25 weeks of pregnancy, and declines toward term (2, 3) . PRL exerts its effect through interaction with single transmembrane-spanning receptors that belong to the superfamily of cytokine receptors (4 -6) . In the nonpregnant endometrium, PRL receptor expression is detected and localized to the stromal and glandular compartments during the mid-late secretory phase of the menstrual cycle (7, 8) . If pregnancy ensues, PRL receptor expression is retained in the decidua and is further expressed in the chorionic cytotrophoblast, placental trophoblast, and amniotic epithelium (9) . The precise role and mechanism of action of PRL in the nonpregnant and pregnant endometrium has not been clarified. The temporal pattern of expression of both PRL and its receptor in the human endometrium suggests a possible role for the hormone in menstrual function and/or the establishment and maintenance of pregnancy. A role for PRL in the regulation of menstruation is not properly established and is inferred from the observations that PRL concentrations in menstrual fluid on day 1 of menses are 5-fold higher than the median peripheral PRL concentrations (10) and that defective secretory endometrium produces less PRL than normal endometrium (11) . On the other hand, a role for PRL in pregnancy is more widely accepted. This view is strongly supported by recent observations in mice after the knockout of the PRL receptor gene. Female mice with a homozygous null mutation of the PRL receptor are sterile, and their uteri are refractory to implantation (12) .
PRL mediates its effect on target cells in part through activation of Jak2 (Janus kinase 2) and different Stat (signal transducer and activator of transcription) proteins, including Stat1 and Stat5 (reviewed in Ref. 13 ). The activated Stat proteins are translocated into the nucleus and subsequently up-regulate the transcription of target promoters that mediate differentiative or mitogenic effects of PRL (14 -18) . PRL receptors expressed in the glandular epithelial cells of the nonpregnant endometrium use the Jak/Stat signaling pathway in vivo (8) . However, the target genes for PRL function in the endometrial glands remain to be established, although it is evident that the putative PRL-inducible genes are regulated in part by the Stat1 and Stat5 proteins (8) .
The following study was designed to investigate the pattern and site of expression of the PRL-inducible early immediate gene interferon regulatory factor-1 (IRF-1) in the human endometrium during the secretory phase of the menstrual cycle. The effect of exogenous PRL on the transcription of the IRF-1 gene was also investigated using human endometrial biopsy samples collected during the late secretory phase. The demonstration of regulation of IRF-1 expression by PRL provides some insight into the possible genes and diverse functions that PRL regulates in the human endometrium.
Materials and Methods

Tissue collection and processing
Normal endometrial tissue was collected with a Pipelle suction curette (Pipelle, Laboratoire CCD, Paris, France) from fertile women with regular menstrual cycles (25-35 days) undergoing gynecological procedures for benign conditions (dysfunctional uterine bleeding, sterilization, pelvic pain). Biopsies were dated from the patient's last menstrual period, and histological dating was consistent with the date of the last menstrual period. Subjects had not been exposed to exogenous hormones for at least 6 months before inclusion in the study. Written informed consent was received before tissue collection, and ethical approval was received from the Lothian Research ethics committee. Tissue collected for ribonuclease (RNase) protection assay (RPA; n ϭ 5; between days 19 and 26 of the menstrual cycle), Northern blot (n ϭ 3; between days 20 and 26 of the menstrual cycle), and Western blot (n ϭ 3; between days 19 and 26 of the menstrual cycle) analyses was snap-frozen in dry ice and subsequently stored at Ϫ70 C. Tissue collected for immunohistochemistry (n ϭ 4; between days 19 and 26 of the menstrual cycle) was fixed by immersion in 10% neutral buffered formalin overnight at 4 C before routine paraffin embedding. Tissue used for in vitro culture (n ϭ 3; between days 24 and 26 of the menstrual cycle) was promptly immersed in RPMI 1640 medium (Sigma Chemical Co., Poole, UK) containing 2 mmol/L l-glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin and transported to the culture facility.
Ribonucleic acid (RNA) extraction, RPA, and Northern blot analysis
RNA was extracted from secretory phase endometrium using TriReagent as recommended by the manufacturer (Sigma Chemical Co.). RNA yields were estimated by spectrophotometry at 260 nm. A homologous 260-bp IRF-1 complementary DNA (cDNA) probe was generated by PCR from a clone containing the human IRF-1 cDNA (the clone was a gift from the UK Human Genome Mapping Project Resource Center, Cambridgeshire, UK) and primers at position 829 -850 bp (IRF-For, 5Ј-GAGCCAGAAATTGACAGCCCAG) and 1069 -1089 bp (IRF-1D, 5Ј-GCTACGGTGCACAGGGAATGG-3Ј). The amplified PCR product was subcloned into pCRII, and its identity and orientation were confirmed after sequencing using the PE Applied Biosystems 373A DNA sequencer and the ABI prism DNA sequencing kit (PE Applied Biosystems, Cheshire, UK).
For the RPA, an antisense complementary RNA (cRNA) probe was prepared from HindIII-linearized pCRII plasmid containing the 260-bp cDNA fragment of the human IRF-1. The RPA was conducted using the Ambion RPA II kit (AMS Biotechnology Europe, Oxfordshire, UK) as instructed by the manufacturer. Briefly, the linearized plasmid was incubated with T7 RNA polymerase for 30 min in the presence of [␣-
32 P]UTP (800 Ci/mmol; Amersham Pharmacia Biotech, Aylesbury, UK) mixed with loading dye [95% formamide, 0.025% bromophenol blue, 0.025% xylene cyanol, 30% glycerol, 0.5 mmol/L ethylenediamine tetraacetate (EDTA), and 0.025% SDS] heated at 95 C for 3 min, and separated on a denaturing 5% (wt/vol) acrylamide gel for 3 h at 50 watts. The gel was then covered in Saran wrap and exposed for 2 min to XAR-5 film (Kodak, Bedfordshire, UK) to determine the location of the fulllength radiolabeled cRNA. The appropriate portion of the gel was cut out, placed in an Eppendorf tube together with 350 L elution buffer [containing 0.5 mol/L ammonium acetate, 1 mmol/L EDTA, and 0.2% (wt/vol) SDS], and incubated overnight at 37 C. The activities of two 1-L aliquots were determined by liquid scintillation spectroscopy. The average of the samples was determined, and the volume of radiolabeled probe required to give 2 ϫ 10 5 cpm was calculated. Total RNA (10 g) from secretory phase endometrium and yeast (n ϭ 2; used as reaction controls in the presence or absence of RNase digestion to establish the specificity of the hybridization reaction and the size of the unprotected RNA fragment) was mixed with the radiolabeled probe and hybridization buffer, heated to 90 C for 4 min, and incubated overnight at 45 C. The integrity of RNA and the relative amount of total RNA in each reaction were determined by including radiolabeled cRNA prepared from an 18S ribosomal standard cDNA in each reaction. The next day, single stranded RNA were digested using 250 U/mL RNase A and 10,000 U/mL RNase T1 at 37 C for 30 min. The protected RNA was precipitated and resuspended in gel loading buffer (95% formamide, 0.025% xylene cyanol, 0.025% bromophenol blue, 0.5 mmol/L EDTA, and 0.025% SDS), heated at 95 C for 3 min, and separated on a 5% acrylamide gel under denaturing conditions. The gel was dried under vacuum and initially exposed to a phosphorescent screen (Molecular Dynamics, UK) followed by exposure to autoradiographic film (XAR-5, Kodak).
Northern hybridization was conducted as previously described (19) . Briefly, samples of 10 g total RNA from secretory phase endometrium were electrophoresed through a 1% agarose-2.2 mol/L formaldehyde gel and transferred to Hybond-N ϩ membrane (Amersham Pharmacia Biotech) by capillary blotting. The RNA was fixed to the membrane by 3-min UV transillumination and prehybridized at 65 C for 4 h in 1% BSA, 1 mmol/L EDTA, 0.5 mol/L NaHPO 4 , 7% SDS, and 100 g denatured salmon sperm DNA. The membranes were then hybridized overnight at 65 C in the prehybridization buffer in the presence of 10 6 cpm/mL [␣- 
Western blot analysis
Secretory phase endometrium was homogenized in 500 L lysis buffer [60 mmol/L Tris-HCl (pH 6.8), 1 mmol/L sodium vanadate, 10% glycerol, and 2% SDS] containing protease inhibitors (44 g/mL aprotinin and 1 mmol/L phenylmethylsulfonylfluoride). The insoluble material was discarded by centrifugation, and 50 g lysate protein were boiled for 5 min in an equal volume of sample buffer [125 mmol/L Tris-HCl (pH 6.8), 4% SDS, 2.5% ditiothreiotol, 20% glycerol, and 0.05% bromophenol blue]. The proteins were loaded on a 7.5% polyacrylamide gel, transferred to a polyvinylidene difluoride membrane (Millipore Corp., Bedfordshire, UK), and subjected to immunoblot analysis with a polyclonal rabbit antihuman IRF-1 antibody for 2 h at room temperature. The IRF-1 antibody (Autogenbioclear, Wiltshire, UK) was raised against a 20-amino acid synthetic peptide corresponding to residues 306 -325 of the carboxyl-terminus of human IRF-1 sequence. Subsequently, the membranes were incubated with an antirabbit IgG conjugated to horseradish peroxidase 
Histology and immunohistochemistry
Five-micron sections of mid to late secretory phase human endometrium were cut and mounted on slides coated with 2% TESPA in acetone.
Slides were then dried overnight at 50 C before dewing in Histoclear (National Diagnostics, Hull, UK). Tissues were rehydrated in graded ethanol and washed in water followed by 0.05 mol/L Tris-HCl (pH 7.4) and 0.85% NaCl (TBS). Sections were treated with 10% hydrogen peroxide in methanol for 30 min and then blocked for 30 min with normal swine serum (NSS) diluted 1:5 in TBS and 5% BSA. The polyclonal IRF-1 and PRL receptor (7, 8) antibody were diluted in NSS-TBS and 5% BSA and incubated on the sections overnight at 4 C under plastic coverslips. Control sections were incubated with nonimmune rabbit serum. After removal of coverslips, sections were washed twice in TBS (5 min each time), incubated for 30 min with biotinylated swine antirabbit IgG (DAKO Corp., Buckinghamshire, UK) diluted 1:500 in NSS-TBS, then washed again twice in TBS (5 min each time) and incubated with peroxidase-antiperoxidase conjugated to avidin-biotin complex (DAKO Corp.) for 30 min at room temperature. Color reaction was developed by incubation in a mixture of 0.05% 3,3Ј-diaminobenzidine (Sigma Chemical Co.) in 10 mL 0.05 mol/L Tris-HCl buffer (pH 7.4) and 0.033% hydrogen peroxide.
In vitro culture and PRL regulation of IRF-1 expression
Secretory phase human endometrium (n ϭ 3) collected between days 24 -26 was washed in PBS (prewarmed to 37 C) twice and subsequently minced thoroughly with fine scissors. The biopsy was divided into five aliquots. One aliquot (time zero) was snap-frozen in dry ice at the beginning of the experiment and used as a control. The other four aliquots were cultured in 2 mL RPMI 1640 medium (containing 2 mmol/L l-glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin) with 10 g/mL cycloheximide (Sigma Chemical Co.) and in the absence or presence of 100 ng/mL human PRL (hPRL-SIAFP-B2, donated by NIDDK, NIH). The tissue was incubated in a 37 C incubator with 5% CO 2 for 2 and 4 h and subsequently snap-frozen on dry ice and stored at Ϫ20 C.
After culture, RNA was extracted from the endometrial tissue, and 10 g total RNA were used in RPA as described above to assess the upregulation of IRF-1 by PRL. The relative amounts of IRF-1 RNA and 18S ribosomal standard were determined on a PhosphorImager (Molecular Dynamics, Inc., Sunnyvale, CA), and the 18S ribosomal standard was used to correct for loading variations in the RNA between treatments. Values for background IRF-1 expression established at time zero were subtracted from values at 2 and 4 h in each experiment. The RPA for each individual was repeated three times, and average relative density units were established to calculate the overall mean Ϯ sem for the expression of IRF-1 after treatment with PRL. The fold induction represents IRF-1 expression in the presence of PRL divided by IRF-1 expression in the absence of PRL detected after culture for 2 or 4 h. Differences between the relative density units of IRF-1 and fold induction in the different treatment groups were evaluated using ANOVA, and pairwise comparisons were conducted using Fisher's protected least significant difference test.
Results
The expression of the transcription factor IRF-1 in the human endometrium during the secretory phase of the menstrual cycle was demonstrated initially by RPA using total RNA collected from fertile women between days 19 -26 of the menstrual cycle (Fig. 1) . In all samples a protected fragment of the expected size was detected. Northern and Western blot analyses further confirmed the expression of IRF-1 in the secretory phase human endometrium. The IRF-1 gene was encoded by a single RNA transcript of approximately 2.1 kb (Fig. 2) and a protein of approximately 48 kDa (Fig. 3) . Immunohistochemistry was conducted on human endometrium during the mid to late secretory phase of the menstrual cycle to localize the site of expression of the IRF-1 gene. IRF-1 gene expression was detected predominantly in the glandular epithelial compartment (Fig. 4) . However, IRF-1 expression was not evident in the stromal compartment of the uterus. Sections from the same blocks of uterine tissue were subjected to immunohistochemistry with PRL receptor to confirm the similar pattern of expression of the receptor in these tissues, as has been previously described (7, 8) . In all uterine samples, PRL receptor expression was localized to the endometrial epithelial cells (Fig. 4) as previously reported in the mid to late secretory phase human endometrium (7, 8) and displayed a pattern of expression similar to that observed with the IRF-1 antibody.
To investigate the effect of PRL on the expression of IRF-1 gene in the secretory phase endometrium, we cultured human endometrium tissue collected between days 24 -26 of the menstrual cycle in the absence or presence of 100 ng/mL human PRL for 2 or 4 h. Culture of endometrial tissue with PRL for 2 h resulted in a significant increase in IRF-1 expression (36 Ϯ 3 vs. 110 Ϯ 22 arbitrary units for endometrial tissue incubated in the absence or presence of PRL, respectively; P Ͻ 0.01; Fig. 5, A and B) . IRF-1 expression was significantly reduced when the endometrial tissue was cultured with PRL for 4 h compared with 2 h (110 Ϯ 22 vs. 55 Ϯ 13 arbitrary units after treatment with PRL for 2 and 4 h, respectively; P Ͻ 0.05; Fig. 5, A and B) . There was no significant effect of PRL on the expression of IRF-1 after culture for a 4-h period (31 Ϯ 7 vs. 55 Ϯ 13 arbitrary units for endometrial tissue incubated in the absence or presence of PRL, respectively; Fig. 5, A and B) . Treatment with PRL for 2 h resulted in 2.9 Ϯ 0.4-fold induction of the IRF-1 gene (Fig.  5C) . The fold induction of IRF-1 gene expression was reduced to 1.7 Ϯ 0.1 by 4 h after commencement of treatment (P Ͻ 0.05; Fig. 5C ).
Discussion
The data presented in this study confirm the expression of IRF-1 RNA and protein in the human endometrium during the secretory phase of the menstrual cycle. IRF-1 in human endometrium is encoded by a RNA transcript of approximately 2.1 kb. This is similar to the IRF-1 transcript sizes detected in the Nb2 T cells (20) and a number of rat and mouse tissues, including stomach, intestine, spleen, liver, kidney, brain, heart, lung, and heart (20, 21) . The IRF-1 protein expressed in the human endometrium was approxi- mately 48 kDa in size. This is similar to previous reports on the size of the IRF-1 protein observed in other cell types (22) .
The site of expression of IRF-1 in the human endometrium is localized by immunohistochemistry primarily to the glandular epithelial cells and is similar to that observed for the PRL receptor (7, 8) and its associated Jak2 and Stat signaling proteins (8) . The role of PRL in the expression of IRF-1 in the human endometrium was investigated by conducting short term culture of human endometrial explants with exogenous PRL. The culture studies confirm that expression of IRF-1 in the secretory human endometrium is regulated by PRL. The regulation of expression of IRF-1 by PRL is best described in the Nb2 cell line. In those cells, PRL stimulates the biphasic transcription of the IRF-1 gene over a single cell cycle (23) .
The transcription rate is first rapidly induced within 15 min and reaches a peak within 1 h after stimulation. This is followed by a second rise in transcription between 8 -12 h later (23) . In our model, due to limited biological material obtained at biopsy it was not possible to investigate whether PRL mediates biphasic transcription of the IRF-1 gene. However, our data confirm that IRF-1 expression is significantly increased in the secretory human endometrium within the first 2 h after stimulation with PRL and is reduced by 4 h after the start of the culture period.
Signaling of PRL through its membrane-bound receptor to the IRF-1 promoter is mediated through the Jak2 tyrosine kinase and Stat proteins. PRL signaling to the IRF-1 promoter involves phosphorylation of Jak2, which, in turn, phosphorylates tyrosine residues on the receptor cytoplasmic domain, thus leading to the recruitment of Stat factors such as Stat1 and Stat5 proteins (24 -26) . In turn, these Stat proteins become tyrosine phosphorylated, form homodimers or heterocomplexes, translocate to the nucleus, bind to cognate DNA elements, and regulate transcription of target genes such as IRF-1 (26, 27) . Similar intracellular events have been observed in the glandular epithelium of the human endometrium, whereby treatment with exogenous PRL leads to phosphorylation of Jak2 and Stat1/Stat5 proteins in the late secretory human endometrium (8) . This suggests that in vivo signaling of PRL to the IRF-1 promoter in the late secretory human endometrium is also mediated via the Jak2 and Stat1/ Sat5 proteins.
It is important to emphasize that in this study the effect of PRL on transcription of IRF-1 was investigated only in the late secretory phase of the menstrual cycle. This is due to the absence of PRL and PRL receptor expression in endometrium during the proliferative and early secretory phases of the menstrual cycle (7, 8) . The sites of expression of PRL, PRL receptor, and IRF-1 in the human endometrium suggest that transcription of IRF-1 is regulated by PRL in a paracrine fashion. PRL expression in the human endometrium is localized to the stromal compartment (8) , whereas colocalization of expression of the receptor and IRF-1 is restricted to the glandular epithelial compartment. The temporal pattern of expression of PRL and the PRL receptor genes in the glandular epithelial cells suggest that PRL via IRF-1 is mediating a differentiative, rather than a mitogenic, effect in the glandular compartment. This is inferred from the absence of expression of the PRL and its receptor during the proliferative phase of the menstrual cycle, the period during which the glandular epithelial cells are undergoing rapid mitogenesis.
IRF-1 regulates the transcription of an array of target genes that are involved in complex functions ranging from cellular growth, apoptosis, adhesion, neoplastic transformation, viral resistance, to differentiation (26, 28) . The target genes for IRF-1 in the glandular epithelial cells remain to be established. It is reasonable to predict that IRF-1 regulates the expression of an array of genes within the endometrial epithelial cells that would regulate a multitude of functions in the nonpregnant and pregnant human endometrium. Two possible target genes may be inducible nitric oxide synthase (NOS) and interferon-␤. The effect of IRF-1 on the expression of inducible NOS has been elucidated in several studies FIG. 5 . Effect of PRL on transcription of IRF-1 gene in human endometrium collected during the late secretory phase of the menstrual cycle. Human endometrial tissue was incubated in the absence or presence of 100 ng/mL PRL with 10 g/mL cycloheximide for 2 and 4 h. IRF-1 expression was assessed by RPA using [␣-
32 P]UTP-labeled cRNA IRF-1 probe and 10 g total RNA. A, A representative RPA using a day 26 endometrial sample. Lane 1 is control RNA from tissue collected at the start of the experiment and used to calculate background IRF-1 expression; lanes 2 and 3 are RNA samples after culture in the absence or presence of PRL for 2 h, respectively; lanes 4 and 5 are RNA samples after culture in the absence or presence of PRL for 4 h, respectively. Protected fragments of 260 bp were detected in all samples. B, Relative density units of IRF-1 expression in uterine samples cultured in the absence (ϪPRL) or presence (ϩPRL) of PRL for 2 and 4 h. 18S ribosomal RNA standard was used to correct for loading variation in the RNA between treatments. The data are the mean of three independent experiments; each experiment was repeated three times, and the overall mean Ϯ SEM for IRF-1 expression were calculated. The relative density units for IRF-1 expression are significantly higher after culture with PRL for 2 h (**, P Ͻ 0.01). C, Fold induction of IRF-1 expression after treatment with PRL for 2 and 4 h. Fold induction represents IRF-1 expression in the presence of PRL divided by IRF-1 expression in the absence of PRL. Fold induction of IRF-1 expression is significantly higher after culture with PRL for 2 h compared with that after culture for 4 h (*, P Ͻ 0.05). (29 -31) , and an IRF-binding site has been described in the promoter region of inducible NOS (30) . Inducible NOS is expressed in the uterine glandular epithelium, and its expression has been linked to signal transduction mechanisms leading to menstruation (32, 33) . In the event of pregnancy, this transduction mechanism may be suppressed by embryonic factors, leading to maintenance of endometrial integrity and establishment of pregnancy. Similarly, IRF-1 binds to the upstream regulatory region of the interferon-␤ gene (21, 34) and activates reporter plasmids with the interferon-␤ promoter (35) . Interferon-␤ is a known regulator of cell growth, with antiproliferative activity (36, 37) . This function may aid in regulating the growth of glandular epithelial cells and/or the rapidly proliferating and invading trophoblast cells during the mid to late secretory phase of the menstrual cycle.
In conclusion, this study has demonstrated the expression of the transcription factor IRF-1 in the human endometrium during the mid to late secretory phase of the menstrual cycle. IRF-1 expression is localized to the glandular epithelial cells as has been previously demonstrated for PRL receptors in this tissue. IRF-1 expression in the human endometrium is regulated by PRL in a paracrine fashion. The target genes for PRL function via IRF-1 in the human endometrium remain to be elucidated.
